MedTrace Logo

Effect of Pharmacokinetics in Healthy Chinese Subjects

NCT06005714 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-06-29

No results posted yet for this study

Summary

This study is a single-center, open label, self-controlled phase I clinical study, to evaluate the effects of clarithromycin or cyclosporine on pharmacokinetics of deuterium hydrobromide ramidvir tablets in healthy Chinese subjects.

Conditions

  • The Effects of Clarithromycin or Cyclosporine on Pharmacokinetics of Deuterium Hydrobromide Ramidvir Tablets in Healthy Chinese Subjects

Interventions

DRUG

Mindeudesivir hydrobromide tablets and Clarithromycin tablets

Mindeudesivir hydrobromide tablets are administered once at D1 and D4, and clarithromycin tablets are administered twice from D1 to D10.

DRUG

Mindeudesivir hydrobromide tablets and Cyclosporine softgels

Mindeudesivir hydrobromide tablets are administered once at D1 and D4, and cyclosporine sofgels are administered once at D4.

Sponsors & Collaborators

  • Shanghai Vinnerna Biosciences Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Shuang Li · Zhengzhou Sixth People's Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-08-15
Primary Completion
2023-10-31
Completion
2023-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06005714 on ClinicalTrials.gov